Ablynx announces collaboration with Centocor
Advertisement
Ablynx has signed a collaboration agreement with Centocor Research and Development, Inc. Under the terms of the collaboration, the companies will perform joint research funded by Centocor. Applying the unique properties of Nanobodies, the two companies will work jointly on novel approaches for administration and delivery of Nanobody based therapeutics. The financial terms of the collaboration are not disclosed.
Nanobodies are a novel class of therapeutic proteins that combine the beneficial features of conventional antibodies with desirable properties of small molecule drugs. Nanobodies have the affinity and selectivity of conventional antibodies yet are only a fraction of their size. Because of their unique structure and high stability, Nanobodies can address target opportunities that are beyond the reach of conventional antibodies.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous